cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections

Qiang Chen, Gary Morris, Huafang Lai

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

Plants have been extensively investigated for producing human vaccines. However, due to remaining challenges, particularly in the area of upstream and downstream processing, there are still no licensed plant-produced human vaccine products on the market. This research aims to optimize a more scalable, cost-effective, robust, and safer production process for a vaccine candidate that prevents a variety of sexually transmitted infections. We investigated the parameters for transgene bank establishment, efficient biomass production, protein extraction, and product purification. We also studied the stability of the vaccine candidate under various conditions and established a set of analytical assays for characterizing in-process samples as well as the final purified product. The challenges in eliminating endotoxin and addressing compliance with FDA's current Good Manufacturing Practice (cGMP) regulations will also be discussed.

Original languageEnglish (US)
Title of host publicationAmerican Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009
Pages468-473
Number of pages6
Volume1
StatePublished - 2009
EventAmerican Society of Agricultural and Biological Engineers Annual International Meeting 2009 - Reno, NV, United States
Duration: Jun 21 2009Jun 24 2009

Other

OtherAmerican Society of Agricultural and Biological Engineers Annual International Meeting 2009
CountryUnited States
CityReno, NV
Period6/21/096/24/09

Fingerprint

sexually transmitted diseases
good manufacturing practices
Sexually Transmitted Diseases
Vaccines
vaccines
Vaccine Potency
Transgenes
Endotoxins
Biomass
endotoxins
compliance
transgenes
Costs and Cost Analysis
biomass production
markets
Research
Proteins
assays
proteins
sampling

Keywords

  • CGMP
  • Down-stream
  • Large-scale
  • Processing
  • Purification
  • Vaccine

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)

Cite this

Chen, Q., Morris, G., & Lai, H. (2009). cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections. In American Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009 (Vol. 1, pp. 468-473)

cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections. / Chen, Qiang; Morris, Gary; Lai, Huafang.

American Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009. Vol. 1 2009. p. 468-473.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Chen, Q, Morris, G & Lai, H 2009, cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections. in American Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009. vol. 1, pp. 468-473, American Society of Agricultural and Biological Engineers Annual International Meeting 2009, Reno, NV, United States, 6/21/09.
Chen Q, Morris G, Lai H. cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections. In American Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009. Vol. 1. 2009. p. 468-473
Chen, Qiang ; Morris, Gary ; Lai, Huafang. / cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections. American Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009. Vol. 1 2009. pp. 468-473
@inproceedings{687392844b44447aa1cac60042d2f69b,
title = "cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections",
abstract = "Plants have been extensively investigated for producing human vaccines. However, due to remaining challenges, particularly in the area of upstream and downstream processing, there are still no licensed plant-produced human vaccine products on the market. This research aims to optimize a more scalable, cost-effective, robust, and safer production process for a vaccine candidate that prevents a variety of sexually transmitted infections. We investigated the parameters for transgene bank establishment, efficient biomass production, protein extraction, and product purification. We also studied the stability of the vaccine candidate under various conditions and established a set of analytical assays for characterizing in-process samples as well as the final purified product. The challenges in eliminating endotoxin and addressing compliance with FDA's current Good Manufacturing Practice (cGMP) regulations will also be discussed.",
keywords = "CGMP, Down-stream, Large-scale, Processing, Purification, Vaccine",
author = "Qiang Chen and Gary Morris and Huafang Lai",
year = "2009",
language = "English (US)",
isbn = "9781615673629",
volume = "1",
pages = "468--473",
booktitle = "American Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009",

}

TY - GEN

T1 - cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections

AU - Chen, Qiang

AU - Morris, Gary

AU - Lai, Huafang

PY - 2009

Y1 - 2009

N2 - Plants have been extensively investigated for producing human vaccines. However, due to remaining challenges, particularly in the area of upstream and downstream processing, there are still no licensed plant-produced human vaccine products on the market. This research aims to optimize a more scalable, cost-effective, robust, and safer production process for a vaccine candidate that prevents a variety of sexually transmitted infections. We investigated the parameters for transgene bank establishment, efficient biomass production, protein extraction, and product purification. We also studied the stability of the vaccine candidate under various conditions and established a set of analytical assays for characterizing in-process samples as well as the final purified product. The challenges in eliminating endotoxin and addressing compliance with FDA's current Good Manufacturing Practice (cGMP) regulations will also be discussed.

AB - Plants have been extensively investigated for producing human vaccines. However, due to remaining challenges, particularly in the area of upstream and downstream processing, there are still no licensed plant-produced human vaccine products on the market. This research aims to optimize a more scalable, cost-effective, robust, and safer production process for a vaccine candidate that prevents a variety of sexually transmitted infections. We investigated the parameters for transgene bank establishment, efficient biomass production, protein extraction, and product purification. We also studied the stability of the vaccine candidate under various conditions and established a set of analytical assays for characterizing in-process samples as well as the final purified product. The challenges in eliminating endotoxin and addressing compliance with FDA's current Good Manufacturing Practice (cGMP) regulations will also be discussed.

KW - CGMP

KW - Down-stream

KW - Large-scale

KW - Processing

KW - Purification

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=76549131822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549131822&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:76549131822

SN - 9781615673629

VL - 1

SP - 468

EP - 473

BT - American Society of Agricultural and Biological Engineers Annual International Meeting 2009, ASABE 2009

ER -